autoimmune Archives - Journal for Clinical Studies

Current Edition

news

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment o...

13 December 2017 news antibody | autoimmune

Continue Reading →

news

Ozanimod Superior to Avonex in Treating Relapsing MS in Phase 3 Trials, Celgene Reports

Celgene released the results of two Phase 3 trials showing that patients with relapsing multiple sclerosis (MS) who were treated with ozanimod had lower relapse rates...

22 November 2017 news autoimmune | FDA

Continue Reading →

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Rare Disease Ebook

Vaccine – Shorten Start-Up Timelines in Vaccine Trials

Current Edition

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

Ozanimod Superior to Avonex in Treating Relapsing MS in Phase 3 Trials, Celgene Reports

Journal for Clinical Studies